Ranbaxy gets agency nod for generic Biaxin suspension
Clarithromycin oral suspension approved for Ranbaxy Pharmaceuticals
Clarithromycin for Oral Suspension, USP, has been approved by the FDA for Ranbaxy Pharmaceuticals in strengths of 125 mg/5 ml and 250 mg/5 ml. The agent is bioequivalent to Biaxin Granules in the same strengths from Abbott Laboratories. Clarithromycin is indicated for the treatment of mild to moderate infections causes by susceptible microorganisms.
Click here to see more articles from Drug Topics Daily News.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
